De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion.


Journal

Hematology (Amsterdam, Netherlands)
ISSN: 1607-8454
Titre abrégé: Hematology
Pays: England
ID NLM: 9708388

Informations de publication

Date de publication:
Dec 2022
Historique:
entrez: 30 11 2022
pubmed: 1 12 2022
medline: 2 12 2022
Statut: ppublish

Résumé

We herein describe two cases of de novo lymphoid blastic transformation in patients with no history of chronic-phase chronic myeloid leukemia (CP-CML), both of whom were labeled initially as Philadelphia positive B-Acute Lymphoblastic Leukemia (B-ALL). The first patient was an 18-year-old male who presented with subjective fever, intentional weight loss, generalized fatigue, and headache. Investigations showed leukocytosis (312 × 10^3/ul), thrombocytopenia and anemia. Flowcytometry was consistent with B-ALL, with aberrant expression of CD13 and CD33. He was found to be positive for De novo lymphoid blastic-phase CML can therefore be difficult to differentiate from Philadelphia positive B-ALL due to their overlapping clinical and laboratory picture, implying the need to do myeloid compartment evaluation at the time of diagnosis. With recent progress in the treatment of Philadelphia positive B-ALL, including the role of transplant with the use of novel agents, a better characterization of this disease entity in retrospective and prospective trials is warranted.

Identifiants

pubmed: 36448578
doi: 10.1080/16078454.2022.2150386
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1259-1262

Auteurs

Maha Hameed (M)

College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.

Mohammed Alnoamani (M)

Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.

Mohammed Marei (M)

Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.

Imran Tailor (I)

Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.

Hassan Alshehri (H)

Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.

Soha A Tashkandi (SA)

Cytogenetics Laboratory, Department of Clinical Pathology, King Fahad Medical City, Riyadh, Saudi Arabia.

Azizah Alswayyed (A)

Cytogenetics Laboratory, Department of Clinical Pathology, King Fahad Medical City, Riyadh, Saudi Arabia.

Abdullah M Alrajhi (AM)

Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia.
Department of Pharmacy Practice, College of Pharmacy, AlFaisal University, Riyadh, Saudi Arabia.

Syed Z A Zaidi (SZA)

Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.

Ibraheem Motabi (I)

Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.

Nawal AlShehry (N)

Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.

Mansour Alfayez (M)

College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.
Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH